Hormones and Female Urinary Incontinence

激素和女性尿失禁

• 批准号: 7586849
• 负责人: TOM F LUE
• 金额: $ 28.86万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7586849
• 关键词: Adrenergic Receptor; Affect; Birth trauma; Bladder; Bladder Control; Cell Culture Techniques; Cell Proliferation; Cells; Clinical; Development; Estradiol; Estrogens; Factor Analysis; Female; Ganglia; Genes; Goals; Gonadal Steroid Hormones; Growth Factor; Health Expenditures; Hormonal; Hormones; Human; Incidence; Incontinence; Knowledge; Longitudinal Studies; Measures; Medical; Modeling; Molecular; Muscle; Myosin Light Chains; Myxoid cyst; Nerve; Neurons; Operative Surgical Procedures; Ovariectomy; Pathway interactions; Pelvic Floor Muscle; Pelvic floor structure; Phosphorylation; Pilot Projects; Placebos; Pregnancy; Prevalence; Prevention; Preventive; Progesterone; Publishing; Quality of life; Raloxifene; Rattus; Rho-associated kinase; Risk Factors; Selective Estrogen Receptor Modulators; Smooth Muscle Myocytes; Somatotropin; Stress; Stress Urinary Incontinence; Testing; Testosterone; Therapeutic; Time; Urethra; Urinary Incontinence; Vagina; Vaginal delivery procedure; Vascular Endothelial Growth Factors; Woman; age group; improved; levormeloxifene; men; middle age; neurite growth; older women; promoter; relating to nervous system; research study

DESCRIPTION (provided by applicant): It is estimated that 100 million men and women are affected by urinary incontinence (UI). The prevalence of UI is generally higher in women than in men, women being between two (older age groups) and four times (younger and middle-aged) more likely to be incontinent than men. Hormone replacement has been the mainstay of medical therapy for women with urinary incontinence for several decades. However, two recently published long-term studies involving thousands of women showed that estrogen/progesterone therapy increased the incontinence rate. We have developed a rat model of stress urinary incontinence (SUI) and have since been actively involved in the study of female SUI. To investigate the hormonal effect on urinary incontinence, we treated our rat SUI models with placebo versus estrogen pellet. Consistent with the results of human studies mentioned above, our pilot study showed that estrogen treatment increased the rate of SUI. We went on to study the possible mechanism of this phenomenon and found that estrogen has differential effects on the vagina and urethra. We hypothesize that the relaxant effect of estrogen on the urethra contributes to the increase incontinence rate particularly in those women who already have "compromised" continence mechanism. We also hypothesize that better treatment options can be identified by studying the effect of selective estrogen receptor modulators (SERMs) as well as several known trophic factors for muscle and nerve. The hypotheses will be tested by completing the following specific aims. Our long term goal is to find better preventive and therapeutic measures for women with urinary incontinence. Specific Aim 1. To identify the effect of sex hormones and SERMs on female urinary continence. This will be accomplished by treating our established incontinence rat model with estrogen, progesterone, raloxifene, levormeloxifene, and growth hormone, followed by cystometrical analysis. Specific Aim 2. To elucidate the molecular mechanism associated with estrogen/progesterone induced incontinence. This will be accomplished by examining the urethra, bladder, vagina, and pelvic floor muscles for possible changes in myosin light chain phosphorylation, rho kinase expression, and VEGF promoter activity. Specific Aim 3. To identify better preventive and therapeutic options for stress urinary incontinence. This will be accomplished first by establishing primary urethra smooth muscle cell cultures and paracervical ganglion neurons from various groups of rats as in Specific Aim 1. The cell and ganglial cultures will be treated with estradiol, raloxifene, testosterone, and various growth factors, and analyzed for cell proliferation and neurite growth. Specific Aim 4. To identify the molecular mechanism through which estrogen modulates the expression of a1A adrenoceptor. This will be accomplished by analyzing various promoter constructs of the rat a1A adrenoceptor gene in the presence of estrogen and SERMs.

描述（由申请人提供）：据估计，1亿男性和女性受到尿失禁（UI）的影响。女性尿失禁的患病率通常高于男性，女性发生尿失禁的可能性是男性的2倍（老年组）至4倍（青年和中年）。几十年来，激素替代疗法一直是治疗女性尿失禁的主要药物。然而，最近发表的两项涉及数千名妇女的长期研究表明，雌激素/孕激素治疗增加了尿失禁率。我们已经建立了一个大鼠模型的压力性尿失禁（SUI），并一直积极参与研究女性SUI。为了研究激素对尿失禁的影响，我们用安慰剂与雌激素颗粒治疗我们的大鼠SUI模型。与上述人类研究结果一致，我们的初步研究表明，雌激素治疗增加了SUI的发生率。我们继续研究这种现象的可能机制，发现雌激素对阴道和尿道有不同的影响。我们推测，雌激素对尿道的松弛作用有助于增加尿失禁率，特别是在那些已经有“妥协”的尿道机制的妇女中。我们还假设，通过研究选择性雌激素受体调节剂（SERM）以及几种已知的肌肉和神经营养因子的作用，可以确定更好的治疗方案。将通过完成以下具体目标来检验假设。我们的长期目标是找到更好的预防和治疗措施的妇女尿失禁。具体目标1.探讨性激素和血清素对女性泌尿生殖系统的影响。这将通过用雌激素、孕酮、雷洛昔芬、左美洛昔芬和生长激素治疗我们建立的失禁大鼠模型，然后进行膀胱测量分析来实现。具体目标2。探讨雌孕激素诱导尿失禁的分子机制。这将通过检查尿道、膀胱、阴道和骨盆底肌肉中肌球蛋白轻链磷酸化、rho激酶表达和VEGF启动子活性的可能变化来实现。具体目标3。目的探讨压力性尿失禁的预防和治疗方法。这将首先通过建立来自不同大鼠组的原代尿道平滑肌细胞培养物和盲肠旁神经节神经元来实现，如具体目标1中所述。将用雌二醇、雷洛昔芬、睾酮和各种生长因子处理细胞和神经节培养物，并分析细胞增殖和神经突生长。具体目标4。探讨雌激素调节α 1A肾上腺素受体表达的分子机制。这将通过在雌激素和SERM存在下分析大鼠α 1 A肾上腺素受体基因的各种启动子结构来实现。